

*Proposition related to the thesis:*

**Unlocking the Value of Expanded Access**  
Ethical, Statistical, and Policy Considerations

1. Access to unregistered medicines through expanded access offers incidental benefits to patients, but the clinical relevance of the average new drug is limited. *This thesis*
2. Expanded access, initially just a treatment modality, now additionally offers evidence to clinical researchers, regulators, and reimbursement bodies. *This thesis*
3. The lack of harmonization of policies and regulation in the provision of expanded access and associated data collection deters access to unapproved drugs and raises concerns of equity in patient access. *This thesis*
4. Data from expanded access can be statistically incorporated in the analysis of clinical trials through novel Bayesian methods that attenuate measured and unmeasured confounding. *This thesis*
5. The research aspect of expanded access raises a variety of ethical considerations relevant to the future of expanded access, including issues related to data quality, payment, transparency, and institutional review board or research oversight. *This thesis*
6. Traditional RCTs do not necessarily minimize overall harm to current and future patients, especially for life-threatening cancers that currently have no effective therapies. (RCTs) are too lengthy, too conservative, and focused too much on rejecting ineffective drugs and avoiding false-positive results. *Lo et al., JAMA Oncology, 2017*
7. Publiceren met je partner is een wetenschappelijk duet: de één mag variëren op het thema, maar er moet iemand de maat houden.
8. Aut aliquis latet error. *Vergilius. Aeneis. II, l. XLVII*
9. Wij vertrouwen eerder op hoe wij gezien worden dan op hoe wij onszelf zien. *Arthur Japin*
10. Music expresses that which cannot be said and on which it is impossible to be silent. *Victor Hugo*
11. Everything in moderation, including moderation. *Oscar Wilde*